about
Filamin A stabilizes Fc gamma RI surface expression and prevents its lysosomal routingDirect interaction between FcgammaRI (CD64) and periplakin controls receptor endocytosis and ligand binding capacityInteractions between the cytosolic components p47phox and p67phox of the human neutrophil NADPH oxidase that are not required for activation in the cell-free system.Mac-1 (CD11b/CD18) is essential for Fc receptor-mediated neutrophil cytotoxicity and immunologic synapse formation.OS9 interacts with DC-STAMP and modulates its intracellular localization in response to TLR ligation.DC subset-specific induction of T cell responses upon antigen uptake via Fcγ receptors in vivo.Fc receptor inside-out signaling and possible impact on antibody therapy.Plant-derived anti-Lewis Y mAb exhibits biological activities for efficient immunotherapy against human cancer cells.Specificity and Effector Functions of Human RSV-Specific IgG from Bovine Milk.Recombinant Soluble Respiratory Syncytial Virus F Protein That Lacks Heptad Repeat B, Contains a GCN4 Trimerization Motif and Is Not Cleaved Displays Prefusion-Like Characteristics.Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages.Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.Disturbed interaction of p21-rac with mutated p67-phox causes chronic granulomatous diseaseA comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA.Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targetingMCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL.Functional characteristics of the high affinity IgG receptor, FcγRI.Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer.IgA as therapeutic antibody.Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing.Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2m(1) antibody.IgG antibodies in food allergy influence allergen-antibody complex formation and binding to B cells: a role for complement receptors.Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing.The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden.Cytokine-induced immune complex binding to the high-affinity IgG receptor, FcγRI, in the presence of monomeric IgG.The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking.Inside-out regulation of Fc alpha RI (CD89) depends on PP2A.FcgammaRI (CD64) resides constitutively in lipid rafts.Protein 4.1G binds to a unique motif within the Fc gamma RI cytoplasmic tail.Signaling through mutants of the IgA receptor CD89 and consequences for Fc receptor gamma-chain interaction.Direct targeting of genetically modified tumour cells to Fc gammaRI triggers potent tumour cytotoxicity.Human amniotic fluid antibodies protect the neonate against respiratory syncytial virus infection.The FcgammaRIa (CD64) ligand binding chain triggers major histocompatibility complex class II antigen presentation independently of its associated FcR gamma-chain.Interactions between the components of the human NADPH oxidase: a review about the intrigues in the phox family.Targeted delivery of a sialic acid-blocking glycomimetic to cancer cells inhibits metastatic spread.The Fcγ receptor IIA R131H gene polymorphism is associated with endothelial function in patients with hypercholesterolaemia.Serum antibodies critically affect virus-specific CD4+/CD8+ T cell balance during respiratory syncytial virus infections.c-Jun activating binding protein 1 binds to the IgA receptor and modulates protein levels of FcalphaRI and FcRgamma-chain.Staphylococcus aureus formyl peptide receptor-like 1 inhibitor (FLIPr) and its homologue FLIPr-like are potent FcγR antagonists that inhibit IgG-mediated effector functions.Modulation of FcgammaRI (CD64) ligand binding by blocking peptides of periplakin.
P50
Q24321450-8997C07D-A8BB-494A-A2B0-94C6F18A582FQ24564238-AEF24B63-5515-4247-8CB6-C3FC46388BA0Q30193434-896E24F1-0F44-4829-9279-6A2977EAB5D1Q30985509-473DF3CA-ED55-4D3C-8B9D-39CD0667721AQ33379484-7B262AEF-8AED-49ED-BE03-AF0EB2E1919CQ33627385-669C6454-BC85-4683-AB00-D7BF7E6B6E0DQ34499280-C43E43C5-76AE-4185-815A-3E896B31EFBAQ34695471-202D6AE7-C968-41F6-A5C4-57BB12EE1977Q35399929-2C0ABDB5-B6C3-4DCE-8CA3-5A56DEEB687FQ35672965-E1BF2A3B-EEBB-4D98-BC1D-03C895762059Q36127055-44CC7131-9969-4CAD-A2DD-4EBCFFD07886Q36213094-2AF48B0E-F33F-47CB-AF20-8F4062B77B50Q36367432-43B5F9C0-4B86-4DC5-95B2-374D63E40B0CQ37138274-6DEF7BF2-5BB9-48A1-829F-BCBACA604A3AQ37138332-5359B086-9E4F-4AD7-B98E-1F0CA3E880ADQ37412499-5F9D2196-5B04-4281-85A0-E37E0FFD6989Q37843085-D5222603-6D6E-4406-AA9C-74D72A47F0C2Q38291696-091EE1BC-8C3E-4D08-A937-675D652817A1Q38644411-0A0657F3-366D-4F73-BBDE-F6BBE5658981Q38832457-23C9EA18-EEE4-4645-AF67-B38EBB25BEAFQ39027573-F2E597C9-D8A8-4C82-BEE6-C89B8196834BQ39101281-B70C6A89-EB46-4025-9B69-74E1C99385C2Q39593092-5F70D905-EBDD-4D15-B151-B5EEADFA435AQ39646209-1CF41D4B-453F-407B-BD01-5FB2EF320D0BQ39661537-11E0C9FE-99F5-46F3-AE31-7FFF6255F519Q39674450-634191A1-E90E-4CA0-A08A-A7705C7DAC98Q39943883-205851E8-515B-4EA6-AA4B-A600C4726ADEQ40022575-54CAA866-6D01-4C29-B8EC-1558E52C3D86Q40049130-5D7CAE91-8A1A-4B70-9834-8A11EA5873A6Q40308501-377CBC7E-D298-4F5C-9EAA-44E3B224C7AAQ40330620-4E9525E6-6434-4A37-A368-799FBAB60B85Q40603204-A65A4ACA-4D78-4554-80ED-F5D9F336525FQ40943488-44155DB7-9A5E-4528-9AB6-BE006C2A6441Q41477197-84A1050C-E7BA-4EA1-B8A8-A63C2EEA3A71Q41552892-9CF1193C-CF54-43A1-B4F5-C24239082FD4Q42492553-F52EA5EC-8063-4848-8E00-CF2ABB8AC364Q42819056-3C0CE162-897F-460D-B3BB-3B16A390C8E9Q42827375-AD5CEA49-36C2-4E07-A786-F453FE157969Q44076378-EE10A3F6-9D94-421B-A6F6-2D6177128D24Q44909714-9ECAB02F-FC9D-4FE6-8F2A-60A35A811E10
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jeanette H Leusen
@ast
Jeanette H Leusen
@en
Jeanette H Leusen
@es
Jeanette H Leusen
@nl
type
label
Jeanette H Leusen
@ast
Jeanette H Leusen
@en
Jeanette H Leusen
@es
Jeanette H Leusen
@nl
prefLabel
Jeanette H Leusen
@ast
Jeanette H Leusen
@en
Jeanette H Leusen
@es
Jeanette H Leusen
@nl
P106
P31
P496
0000-0003-4982-6914